Suppose they went for a Neuren/Acadia type deal where ATH got say 10M upfront for a back ended (15-20% net sales) royalty and milestones deal. We would cop the same outrage NEU copped in 2018. We would have sold off this neuro drug for peanuts. Would 100M upfront and 85% of the assets future earnings be good- yes, but nobody will ever offer that. Its too one sided.
I am bitterly dissapointed that I held through the risk and some 'sophs' now get a first look at the future strategy, while I get to try to decipher hotcopper.
My read/hope is that they will seek accelerated approval and look at doing a ph2 Parkinsons study. It would be stupid not to chase PD with 434 if they have the money. Also, If they come out and say they are going for a AA without the money to back the application, the market would punish us the same way the ph2 results were treated underwhelmingly imo.
Its going to be a long 4 days.....
ATH Price at posting:
1.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)